|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Comptoir Group PLC - London-based owner and operator of Lebanese, Middle Eastern and North African inspired restaurants - Pretax loss in six months to June 29 narrows to £69,000 from £2.2 million a year prior, as revenue increases 0.6% to £16.0 million from £15.9 million. On a like-for-like basis, revenue improves 1.6%. ‘Franchise operations continue to be an exciting growth opportunity for the group. Overall performance across our six franchise sites has been strong, particularly our Milan site which opened last year and is trading significantly above expectations. Franchise has always been a low-capital intensive route to increasing presence of our brands, and we will proactively assess whether further opportunities exist,’ Comptoir says. ‘Prevailing market conditions continue to present significant challenges to the hospitality sector. Cost of living pressures and economic uncertainty continue to put pressure on consumer demand and disposable income, placing further strain on our focus for winning back covers. Prudent capital management has positioned the group well to face these challenges, and we continue to strive to offer a genuine value for money, exceptional experience for our guests, despite what economic challenges are facing the industry in 2025 & beyond.’ ---------- Journeo PLC - Ashby-de-la-Zouch, Leicestershire-based provider of information systems and technical services to transport operators and local authorities - Journeo reports slightly weaker half-year earnings. Pretax profit in the first half of 2025 declines 3.5% to £2.7 million from £2.8 million a year prior. Revenue of £24.5 million is reported, down 4.3% from £25.6 million a year earlier. ‘The group continues to perform well and in line with management expectations, keeping Journeo on track to deliver another record year. Strong organic growth in UK revenues, driven by our Fleet Systems and Passenger Systems businesses, is propelling the group forward and has almost entirely offset the US sales delivered by Infotec in H1 2024,’ Chief Executive Officer Russ Singleton says. The firm is on track for ‘another record set of full-year results, in line with market expectations’. ---------- CT Automotive Group PLC - Portsmouth, England-based maker of interior components for the automotive industry - Pretax profit in the first half of 2025 falls 11% to $3.4 million from $3.8 million, while revenue falls 11% to $54.1 million from $60.5 million. Nonetheless, it reports a ‘productive first six months with eight new contracts secured’. These deals are worth $37 million annually, CT says. ‘While the market has been challenging with tariffs adding further complexity, we have remained flexible and responsive to changing customer needs, successfully focusing on new ways to reduce supply chain costs reflected in the new business wins. Our investment in AI, automation and digitisation continue to be key to driving the gross profit margin which has again improved significantly up by 290 basis points. The board has taken the strategic decision to continue the investment in our Mexico facility, driven by demand in this market,’ CEO Simon Phillips says. The company is on track to hit 2025 market expectations, which it puts at $10.5 million for adjusted pretax profit. ---------- Portmeirion Group PLC - Stoke-on-Trent, England-based ceramics maker and retailer of homeware brands - Portmeirion’s pretax loss in the half-year to June 30 widens to £2.9 million from £2.6 million a year prior. Revenue rises 1.3% to £37.1 million from £36.6 million. ‘The introduction of additional import tariffs in the US market caused immediate disruption and significant uncertainty in our largest and most profitable market. We have acted quickly and proactively in our response and continue to monitor the situation closely including how it impacts consumer confidence over the Christmas period. Against this backdrop I’m delighted that we have taken the opportunity to accelerate our Made in Stoke-on-Trent onshoring initiative, increasing the proportion of product supplied into the US that is made in the UK,’ CEO Mike Raybould says. Portmeirion expects US market uncertainty to continue until there is ‘clarity on incremental tariffs, particularly with China’. It has optimism for the medium and long term, however. It adds: ‘The board remains mindful of the challenges ahead in what continues to be an uncertain economic environment and with a significant Q4 weighting for the business. In particular, we are closely monitoring how the US consumer will react to higher prices during the key seasonal period.’ ---------- Mothercare PLC - specialises in clothes and other products for newborn babies and children - Pretax profit in the year ended March 29 jumps to £11.9 million from £2.9 million the year prior. Mothercare’s bottom line gets a £15.2 million boost from the sale of intellectual property. ‘During the year Mothercare and Reliance (our Indian Franchise partner) created a new joint venture. Under the terms of the arrangement, Reliance paid £16.0 million to acquire a 51% interest in a new joint venture Co JVCO 2024 Ltd, which held the Mothercare intellectual property, for certain Asian countries, with Mothercare retaining a 49% residual shareholding. Mothercare earned a net income of £15.2 million from the arrangement,’ it adds. Revenue falls 31% to £38.9 million from £56.2 million. Mothercare swings to an adjusted loss after tax of £2.5 million, from profit of £3.5 million. ‘Whilst we now receive revenues at lower rates than previously, we expect the reinvigorated business to grow strongly and surpass previous revenue levels over the next few years. We also expect to benefit from both sourcing fees (supplying the joint venture with product) together with the value creation accruing to our residual 49% equity stake in JVCo,’ the firm adds. ---------- N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on Nuvec gene delivery system - Pretax loss in first half of 2025 narrows to £470,216 from £491,705 a year prior. Revenue, however, falls to £3.7 million from £3.9 million. N4 says R&D and general expenditure was ‘in line with budget’. ‘The first half of the year has delivered strong progress with N4 Pharma’s focus being on expanding the team to formalise the company’s data package with a view to securing commercial agreements with third parties, whilst advancing its lead preclinical programme, N4 101, and scoping out novel RNA drug development opportunities with Nuvec,’ CEO Nigel Theobald says. ‘Following the company’s successful fundraising in April 2025, N4 Pharma is well placed to undertake the work required to hit key value inflection milestones, building on Nuvec’s proven ability in the use of oral and targeted drug delivery, two areas which represent, both in unison and individually, areas of massive commercial potential.’ ---------- Polarean Imaging PLC - medical imaging technology developer - Pretax loss in first six months of 2025 widens to $5.1 million from $4.0 million. Revenue declines to $594,910 from $1.1 million. ‘Increased consumable sales for H1 2025 by 36% compared to H1 2024, reflecting greater utilization by existing customers; however, there were no Xenon MRI system sales in H1 2025, compared with one in H1 2024,’ Polarean says, also noting a ‘challenging US market for capital equipment’. Looking ahead, it says: ‘As indicated by our backlog of outstanding quotes, we are confident that our commercial strategy is working. However, the proposed NIH grant funding cuts, together with the Medicaid cuts under the recently passed [one big beautiful bill act], have introduced sector-wide uncertainty, leading to delays in purchasing decisions.’ Polarean says these delays have hurt its ability to pen system sales. As a result, it lowers its revenue outlook to a $2.5 million to $3.5 million range, from $5 million to $6 million previously. Revenue in 2024 totalled $3.1 million. ‘We believe that the company will be in a good position to resume a sales growth trajectory in 2026, with a revised revenue target of $5 million to $6 million for 2026,’ it adds. The company also announces an order for a new Xenon MRI System from the National Institutes of Health Clinical Centre in Bethesda, Maryland. ---------- Amicorp FS (UK) PLC - fund services provider - Pretax profit in first half of 2025 rises 59% to $2.5 million from $1.6 million. Revenue is up 7.8% to $9.4 million from $8.7 million. ‘The Board notes the progress achieved in the first half of 2025, particularly with the continued onboarding of new funds and the expansion of capital market mandates. This momentum supports the expectation that the group will maintain steady growth in the second half of the year,’ Amicorp says. ---------- India Capital Growth Fund Ltd - invests in companies based in India - Net asset value per share at June 30 half-year end declines 9.3% to 189.58 pence from 209.01p at the end of December. The decline is due to a weaker Indian rupee. ‘The board is optimistic about the prospects for the Indian economy and for the stock market in India. While there are legitimate concerns about valuations and the speculation taking place in some sectors of the stock market, India’s weighting in the emerging markets indices is increasing and foreign investors are, for the most part, underweight,’ Chair Elisabeth Scott says. ---------- Arkle Resources PLC - exploration company with gold, zinc and lithium assets in Ireland, Botswana and Zimbabwe - Pretax loss in first half of 2025 narrows to €116,000 from €158,000 a year earlier, as administrative expenses fall 30% to €122,000 from €175,000. Arkle reports no revenue, unchanged year-on-year. ---------- Chariot Ltd - upstream oil and gas, renewable power and green hydrogen, and gas projects in Africa - Pretax loss in six months to June 30 narrows to $4.7 million from $8.2 million a year prior. Chariot reports nominal revenue of $78,000, barely budging from $80,000 a year prior. ‘We are excited for the future of Chariot and the clear drivers that we have for the next steps in the evolution of our Upstream and Renewable Power businesses. We will continue to evaluate how best to enact a demerger, and valuations and the markets will be key factors to consider around timing, but we are ready to grow, deliver on the opportunities we have before us and create lasting value,’ Chariot adds. Chariot is looking into how to enact a separation of its renewables business. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
